2-phenylcyclopropan-1-amine has been researched along with vorinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, LN; Duan, YC; Guan, YY; Ma, CY; Ma, YC; Qin, WP; Yang, J; Zhai, XY; Zheng, YC; Zhu, YL | 1 |
| Elboray, EE; Horinaka, M; Hu, C; Itoh, Y; Kurohara, T; Masuda, M; Morita, M; Mukherjee, A; Ota, Y; Sakai, T; Singh, R; Sowa, Y; Suzuki, T; Takada, Y; Yamashita, Y; Zamani, F | 1 |
2 other study(ies) available for 2-phenylcyclopropan-1-amine and vorinostat
| Article | Year |
|---|---|
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Demethylases; Humans; Methylation; Molecular Docking Simulation; Neoplasms; Tranylcypromine | 2017 |
Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.
Topics: | 2022 |